A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors

Lim, Kah Jing; Bisht, Savita; Bar, Eli E.; Maitra, Anirban; Eberhart, Charles G.

doi:10.4161/cbt.11.5.14410

Cited by 207 publications

(129 citation statements)

References 49 publications

(64 reference statements)

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…In vivo studies of PLGA and polyNI-PAM nanogel curcumin formulations have shown improved bioavailability, and therefore are more effective systems for delivering curcumin into tumors. 12,14,16,72,73 These data clearly support the overall conclusion of this study. Our future research efforts will include evaluation of the in vivo pharmacokinetics of these curcumin nanoformulations to clarify the underlying mechanisms for potential cancer therapeutics.…”

supporting

confidence: 81%

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Yallapu¹,

Ebeling²,

Chauhan³

et al. 2011

IJN

View full text Add to dashboard Cite

Background Recent studies report curcumin nanoformulation(s) based on polylactic- co -glycolic acid (PLGA), β-cyclodextrin, cellulose, nanogel, and dendrimers to have anticancer potential. However, no comparative data are currently available for the interaction of curcumin nanoformulations with blood proteins and erythrocytes. The objective of this study was to examine the interaction of curcumin nanoformulations with cancer cells, serum proteins, and human red blood cells, and to assess their potential application for in vivo preclinical and clinical studies. Methods The cellular uptake of curcumin nanoformulations was assessed by measuring curcumin levels in cancer cells using ultraviolet-visible spectrophotometry. Protein interaction studies were conducted using particle size analysis, zeta potential, and Western blot techniques. Curcumin nanoformulations were incubated with human red blood cells to evaluate their acute toxicity and hemocompatibility. Results Cellular uptake of curcumin nanoformulations by cancer cells demonstrated preferential uptake versus free curcumin. Particle sizes and zeta potentials of curucumin nanoformulations were varied after human serum albumin adsorption. A remarkable capacity of the dendrimer curcumin nanoformulation to bind to plasma protein was observed, while the other formulations showed minimal binding capacity. Dendrimer curcumin nanoformulations also showed higher toxicity to red blood cells compared with the other curcumin nanoformulations. Conclusion PLGA and nanogel curcumin nanoformulations appear to be very compatible with erythrocytes and have low serum protein binding characteristics, which suggests that they may be suitable for application in the treatment of malignancy. These findings advance our understanding of the characteristics of curcumin nanoformulations, a necessary component in harnessing and implementing improved in vivo effects of curcumin.

show abstract

supporting

confidence: 81%

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Yallapu¹,

Ebeling²,

Chauhan³

et al. 2011

IJN

View full text Add to dashboard Cite

show abstract

“…In addition to these features, improved cellular uptake and/ or apoptosis induction by CUR nanoformulations result in enhanced anticancer activity in melanoma (Sun et al, 2014b), prostate (Yallapu et al, 2012), cervical Nair et al, 2012;Punfa et al, 2012;Pillai et al, 2014), ovarian (Yallapu et al, 2010a), breast (Yallapu et al, 2010a;Verderio et al, 2013;Mirakabad et al, 2016), colon (Prajakta et al, 2009;, pancreatic (Kim et al, 2011), lung (Teong et al, 2015) medulloblastoma (Lim et al, 2011), glioblastoma (Lim et al, 2011), and oral carcinoma (Popat et al, 2014) cancer cell lines with superior pharmacokinetics . Furthermore, PLGA-PEG nanoparticles are able to enhance the anticancer efficiency of CUR in prostate (Yallapu et al, 2014) and colon (Kim et al, 2011) cancer cell both in vitro and in vivo.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Polyphenols delivery by polymeric materials: challenges in cancer treatment

et al. 2017

View full text Add to dashboard Cite

Nanotechnology can offer different solutions for enhancing the therapeutic efficiency of polyphenols, a class of natural products widely explored for a potential applicability for the treatment of different diseases including cancer. While possessing interesting anticancer properties, polyphenols suffer from low stability and unfavorable pharmacokinetics, and thus suitable carriers are required when planning a therapeutic protocol. In the present review, an overview of the different strategies based on polymeric materials is presented, with the aim to highlight the strengths and the weaknesses of each approach and offer a platform of ideas for researchers working in the field.

show abstract

“…NanoCurc™, a recently developed polymeric NP encapsulating curcumin, significantly reduced clonogenic growth and CD133-positive stem-like population in malignant brain tumors. 22 In addition, NPs conjugated with PEGylated poly(lactic-co-glycolic acid) receive extensive attention and are used widely because of their safety in the clinical trials. 77 Interestingly, salinomycin-loaded NPs conjugated with CD133 aptamers selectively inhibit CD133-positive osteosarcoma both in vitro and in vivo.…”

Section: Cd133mentioning

confidence: 99%

Targeting cancer stem cells by using the nanoparticles

Hong

Jang

Lee

et al. 2015

IJN

View full text Add to dashboard Cite

Cancer stem cells (CSCs) have been shown to be markedly resistant to conventional cancer treatments such as chemotherapy and radiation therapy. Therefore, therapeutic strategies that selectively target CSCs will ultimately lead to better cancer treatments. Currently, accessible conventional therapeutic agents mainly eliminate the bulk tumor but do not eliminate CSCs. Therefore, the discovery and improvement of CSC-targeting therapeutic agents are necessary. Nanoparticles effectively inhibit multiple types of CSCs by targeting specific signaling pathways (Wnt/β-catenin, Notch, transforming growth factor-β, and hedgehog signaling) and/or specific markers (aldehyde dehydrogenases, CD44, CD90, and CD133) critically involved in CSC function and maintenance. In this review article, we summarized a number of findings to provide current information about their therapeutic potential of nanoparticles in various cancer cell types and CSCs.

show abstract

A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors

Cited by 207 publications

References 49 publications

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Polyphenols delivery by polymeric materials: challenges in cancer treatment

Targeting cancer stem cells by using the nanoparticles

Contact Info

Product

Resources

About